There were 114 press releases posted in the last 24 hours and 147,866 in the last 365 days.

Global Alzheimer’s Disease Drugs and Companies Pipeline Review H1 2016

PUNE, INDIA, September 15, 2016 /EINPresswire.com/ -- Alzheimer’s Disease - Pipeline Review, H1 2016

COMPLETE REPORT DETAILS @ https://www.wiseguyreports.com/reports/393578-alzheimer-s-disease-pipeline-review-h1-2016

The, ‘Alzheimer’s Disease - Pipeline Review, H1 2016’, provides an overview of the Alzheimer’s Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alzheimer’s Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer’s Disease and features dormant and discontinued projects.

For more information or any query mail at sales@wiseguyreports.com

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

GET A SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/393578-alzheimer-s-disease-pipeline-review-h1-2016

Scope
- The report provides a snapshot of the global therapeutic landscape of Alzheimer’s Disease
- The report reviews pipeline therapeutics for Alzheimer’s Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Alzheimer’s Disease therapeutics and enlists all their major and minor projects
- The report assesses Alzheimer’s Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alzheimer’s Disease

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alzheimer’s Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alzheimer’s Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents – Major Key Points

Introduction 12
Alzheimer’s Disease Overview 13
Therapeutics Development 14
Alzheimer’s Disease - Therapeutics under Development by Companies 16
Alzheimer’s Disease - Therapeutics under Investigation by Universities/Institutes 35
Alzheimer’s Disease - Pipeline Products Glance 42
Alzheimer’s Disease - Products under Development by Companies 46
Alzheimer’s Disease - Products under Investigation by Universities/Institutes 73
Alzheimer’s Disease - Companies Involved in Therapeutics Development 83
Alzheimer’s Disease - Therapeutics Assessment 287
Drug Profiles 343
Alzheimer’s Disease - Recent Pipeline Updates 1005
Alzheimer’s Disease - Dormant Projects 1130
Alzheimer’s Disease - Discontinued Products 1172
Alzheimer’s Disease - Product Development Milestones 1183
Appendix 1191
…. CONTINUED

For more information or any query mail at sales@wiseguyreports.com

GET EXCLUSIVE DISCOUNT ON THIS REPORT @ https://www.wiseguyreports.com/check-discount/393578-alzheimer-s-disease-pipeline-review-h1-2016

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here